William Deraedt

8.9k citations

56 papers · 2.7k indexed · 2 hit papers · h-index 15

Impact in

Hematology top 0.2%
- Multiple Myeloma Research and Treatments
Oncology top 2%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research

Papers in ⓘ

Hematology 49
- Multiple Myeloma Research and Treatments 47
Genetics 13
- Chronic Lymphocytic Leukemia Research 10

Co-authors: Antonio Palumbo (8 shared papers)María‐Victoria Mateos (17 shared papers)Helgi van de Velde (15 shared papers)Jordan M. Schecter (20 shared papers)Andrew Cakana (16 shared papers)Tamás Masszi (8 shared papers)Ivan Špıčka (6 shared papers)Ming Qi (9 shared papers)
Journals: Blood (15 papers)Journal of Clinical Oncology (5 papers)Haematologica (2 papers)Current Medical Research and Opinion (2 papers)Clinical Lymphoma Myeloma & Leukemia (10 papers)
Partner nations: United States Belgium Germany

In The Last Decade

William Deraedt

52 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma 2016 · 1.1k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 New England Journal of Medicine
2011 The Lancet Oncology

Peers

Countries citing papers authored by William Deraedt

Since Specialization

Citations

This map shows the geographic impact of William Deraedt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Deraedt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Deraedt more than expected).

Fields of papers citing papers by William Deraedt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Deraedt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Deraedt. The network helps show where William Deraedt may publish in the future.

Co-authors

The 25 scholars most cited alongside William Deraedt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with William Deraedt Line = papers co-authored together William Deraedt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 56 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma New England Journal of Medicine ·Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel, Ajay K. Nooka, Tamás Masszi, Meral Beksaç, Ivan Špıčka, Vânia Hungria, (unknown), María‐Victoria Mateos, Tomer M. Mark, Ming Qi, Jordan M. Schecter, Himal Amin, Xiang Qin, William Deraedt, Tahamtan Ahmadi, Andrew Spencer, Pieter Sonneveld Hit paper breakdown →	2016	1056
2	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study The Lancet Oncology ·Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Maria Grishunina, Grigoriy Rekhtman, Zvenyslava Masliak, Tadeusz Robak, A. V. Shubina, Bertrand Arnulf, Martin Kropff, James Cavet, Dixie‐Lee Esseltine, Huaibao Feng, Suzette Girgis, Helgi van de Velde, William Deraedt, Jean‐Luc Harousseau Hit paper breakdown →	2011	661
3	Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma Haematologica ·H. J.K. van de Velde, X. Liu, George Chen, Andrew Cakana, William Deraedt, M. Bayssas	2007	199
4	VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study Journal of Clinical Oncology ·Meletios Α. Dimopoulos, Paul G. Richardson, Rudolf Schlag, Nuriet K. Khuageva, Ofer Shpilberg, Efstathios Kastritis, Martin Kropff, Maria Teresa Petrucci, Michel Delforge, Julia Alexeeva, Rik Schots, Tamás Masszi, María-Victoria Mateos, William Deraedt, Kevin Liu, Andrew Cakana, Helgi van de Velde, Jesús F. San Miguel	2009	119
5	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study European Journal Of Haematology ·Meletios Α. Dimopoulos, María-Victoria Mateos, Paul G. Richardson, Rudolf Schlag, Nuriet K. Khuageva, Ofer Shpilberg, Martin Kropff, Ivan Špıčka, Antonio Palumbo, Ka Lung Wu, Dixie‐Lee Esseltine, Kevin Liu, William Deraedt, Andrew Cakana, Helgi van de Velde, Jesús F. San Miguel	2010	100
6	Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma Haematologica ·Bertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Helgi van de Velde, H. Feng, Andrew Cakana, William Deraedt, Philippe Moreau	2012	87
7	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone Blood ·Jean‐Luc Harousseau, Antonio Palumbo, Paul G. Richardson, Rudolf Schlag, Meletios Α. Dimopoulos, Ofer Shpilberg, Martin Kropff, Alain Kentos, Michèle Cavo, А К Голенков, Mieczysław Komarnicki, María‐Victoria Mateos, Dixie‐Lee Esseltine, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesús F. San Miguel	2010	79
8	Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma Clinical Pharmacokinetics ·Philippe Moreau, Ievgenii Karamanesht, Н. П. Домникова, Maryna Kyselyova, Kateryna Vilchevska, Vadim Doronin, Alexander Schmidt, Cyrille Hulin, Xavier Leleu, Dixie‐Lee Esseltine, Karthik Venkatakrishnan, Donna Skee, Huaibao Feng, Suzette Girgis, Andrew Cakana, Helgi van de Velde, William Deraedt, Thierry Façon	2012	68
9	Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma Current Medical Research and Opinion ·Tom Martin, Saad Z. Usmani, Jordan M. Schecter, Martin Vogel, Carolyn C. Jackson, William Deraedt, Hong Tian, Tzu‐Min Yeh, Arnob Banerjee, Lida Pacaud, Ashraf Garrett, Anja Haltner, Chris Cameron, Suzy Van Sanden, Joris Diels, Satish Valluri, Imtiaz A. Samjoo	2021	34
10	Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor Blood ·María‐Victoria Mateos, Jane Estell, Wolney Barreto, Paolo Corradini, Chang‐Ki Min, Eva Medvedova, Ming Qi, Jordan M. Schecter, Himal Amin, Xiang Qin, William Deraedt, Tineke Casneuf, Christopher Chiu, A. Kate Sasser, Ajay K. Nooka	2016	28
11	Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5) Blood ·Dominik Dytfeld, Binod Dhakal, Mounzer Agha, Salomon Manier, Michel Delforge, Steven Kuppens, Salma Afifi, William Deraedt, Agne Taraseviciute-Morris, Jordan M. Schecter, Jane Gilbert, Fevzi Yalniz, Erika Florendo, Lida Pacaud, Vânia Hungria, Saad Z. Usmani, María‐Victoria Mateos	2021	26
12	Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. Journal of Clinical Oncology ·Saad Z. Usmani, Jesús G. Berdeja, Deepu Madduri, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, Tzu‐Min Yeh, Yunsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Alicia J. Allred, Enrique Zudaire, William Deraedt, Xiaoling Wu, Marlene J. Carrasco-Alfonso, Muhammad Akram, Yi Lin, Thomas G. Martin, Sundar Jagannath	2021	26
13	Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy Blood ·Michael Wang, André Goy, Peter Martin, Rod Ramchandren, Julia Alexeeva, Rakesh Popat, Irit Avivi, Ranjana H. Advani, Steven Le Gouill, Netanel A. Horowitz, Zhilong Yuan, Britte Kranenburg, Aleksandra Rizo, Sen Hong Zhuang, William Deraedt, Simon Rule	2014	24
14	Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) Blood ·Sriram Balasubramanian, Michael Schäffer, William Deraedt, Cuc Davis, Emily Stepanchick, Regina Aquino, Zhilong Yuan, Britte Kranenburg, Irit Avivi, Martin Dreyling, Simon Rule, Michael Wang, Sen Hong Zhuang, Aleksandra Rizo, Georg Lenz	2014	23
15	Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. Journal of Clinical Oncology ·Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel, Ajay K. Nooka, Tamás Masszi, Meral Beksaç, Ivan Špıčka, Vânia Hungria, María‐Victoria Mateos, Tomer M. Mark, Ming Qi, Jordan M. Schecter, Himal Amin, Xiang Qin, William Deraedt, Tahamtan Ahmadi, Andrew Spencer, Pieter Sonneveld	2016	19
16	Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone Blood ·Jean‐Luc Harousseau, Antonio Palumbo, Paul G. Richardson, Rudolf Schlag, Meletios Α. Dimopoulos, Ofer Shpilberg, Martin Kropff, Michel Delforge, Rik Schots, Michèle Cavo, А К Голенков, Mieczysław Komarnicki, María‐Victoria Mateos, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesús F. San Miguel	2008	13
17	UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA Hematology Transfusion and Cell Therapy ·S.Z. Usmani, J. G. Berdeja, Andrzej Jakubowiak, M Agha, AD Cohen, Deepu Madduri, Parameswaran Hari, T.‐J. Yeh, Yunsi Olyslager, Arnob Banerjee, Jackson Cc, Alicia J. Allred, Enrique Zudaire, William Deraedt, Xiaoxiao Wu, Lida Pacaud, Muhammad Akram, Yukang Lin, Thomas G. Martin, Sundar Jagannath	2021	12
18	Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma Current Medical Research and Opinion ·Tom Martin, Saad Z. Usmani, Jordan M. Schecter, Tito Roccia, Carolyn C. Jackson, William Deraedt, Tzu‐Min Yeh, Arnob Banerjee, Lida Pacaud, Ashraf Garrett, Meaghan Bartlett, Anja Haltner, Suzy Van Sanden, Joris Diels, Satish Valluri, Imtiaz A. Samjoo	2022	12
19	Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Clinical Lymphoma Myeloma & Leukemia ·Andrzej Jakubowiak, Saad Z. Usmani, Amrita Krishnan, Sagar Lonial, Raymond L. Comenzo, Jianping Wang, Carla de Boer, William Deraedt, Brendan M. Weiss, Jordan M. Schecter, Ajai Chari	2021	10
20	Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma Clinical Lymphoma Myeloma & Leukemia ·Katja Weisel, Amrita Krishnan, Jordan M. Schecter, Martin Vogel, Carolyn C. Jackson, William Deraedt, Tzu‐Min Yeh, Arnob Banerjee, Fevzi Yalniz, Tonia Nesheiwat, Suzy Van Sanden, Joris Diels, Satish Valluri, Saad Z. Usmani, Jesús G. Berdeja, Sundar Jagannath, Tom Martin	2022	10

About William Deraedt

William Deraedt is a scholar working on Hematology, Genetics, Oncology, Pathology and Forensic Medicine and Infectious Diseases, having authored 56 papers that have together received 2.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (47 papers), Protein Degradation and Inhibitors (19 papers), Chronic Lymphocytic Leukemia Research (10 papers), CAR-T cell therapy research (10 papers), Cancer Treatment and Pharmacology (8 papers), HIV/AIDS drug development and treatment (7 papers), Peptidase Inhibition and Analysis (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). The work is most often cited by research in Hematology (2.2k citations), Oncology (1.5k citations), Genetics (410 citations), Molecular Biology (1.7k citations) and Pathology and Forensic Medicine (199 citations). William Deraedt has collaborated with scholars based in United States, Belgium and Germany. Frequent co-authors include Antonio Palumbo, María‐Victoria Mateos, Helgi van de Velde, Jordan M. Schecter, Andrew Cakana, Tamás Masszi, Ivan Špıčka, Ming Qi, Ajay K. Nooka and Himal Amin. Their work appears in journals such as Blood, Journal of Clinical Oncology, Haematologica, Current Medical Research and Opinion and Clinical Lymphoma Myeloma & Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact